FR18C1008I2 - Regime posologique de cladribine pour le traitement de la sclerose en plaques - Google Patents

Regime posologique de cladribine pour le traitement de la sclerose en plaques

Info

Publication number
FR18C1008I2
FR18C1008I2 FR18C1008C FR18C1008C FR18C1008I2 FR 18C1008 I2 FR18C1008 I2 FR 18C1008I2 FR 18C1008 C FR18C1008 C FR 18C1008C FR 18C1008 C FR18C1008 C FR 18C1008C FR 18C1008 I2 FR18C1008 I2 FR 18C1008I2
Authority
FR
France
Prior art keywords
cladribine
treatment
multiple sclerosis
dosage regimen
regimen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR18C1008C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR18C1008(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono SA filed Critical Merck Serono SA
Publication of FR18C1008I1 publication Critical patent/FR18C1008I1/fr
Application granted granted Critical
Publication of FR18C1008I2 publication Critical patent/FR18C1008I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FR18C1008C 2004-12-22 2018-02-14 Regime posologique de cladribine pour le traitement de la sclerose en plaques Active FR18C1008I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
EP05823474A EP1827461B1 (fr) 2004-12-22 2005-12-20 Régime posologique de cladribine pour le traitement de la sclérose en plaques
PCT/EP2005/056954 WO2006067141A1 (fr) 2004-12-22 2005-12-20 Schema posologique a base de cladribine destine a traiter la sclerose en plaques

Publications (2)

Publication Number Publication Date
FR18C1008I1 FR18C1008I1 (fr) 2018-03-30
FR18C1008I2 true FR18C1008I2 (fr) 2019-03-01

Family

ID=36227798

Family Applications (1)

Application Number Title Priority Date Filing Date
FR18C1008C Active FR18C1008I2 (fr) 2004-12-22 2018-02-14 Regime posologique de cladribine pour le traitement de la sclerose en plaques

Country Status (24)

Country Link
US (2) US7713947B2 (fr)
EP (6) EP2275110B1 (fr)
JP (7) JP5795456B2 (fr)
KR (1) KR20070091662A (fr)
AR (1) AR052830A1 (fr)
AU (2) AU2005318190B2 (fr)
BR (1) BRPI0517132B8 (fr)
CA (2) CA3087419C (fr)
CY (3) CY1112614T1 (fr)
DK (2) DK2805723T3 (fr)
EA (1) EA015799B1 (fr)
ES (1) ES2921858T3 (fr)
FR (1) FR18C1008I2 (fr)
HR (1) HRP20120228T1 (fr)
HU (2) HUE059133T2 (fr)
IL (2) IL183930A0 (fr)
LT (2) LT3332789T (fr)
LU (1) LUC00064I2 (fr)
MX (1) MX2007007610A (fr)
NO (1) NO20073813L (fr)
PL (3) PL1827461T3 (fr)
SG (1) SG160391A1 (fr)
SI (2) SI2805723T1 (fr)
WO (1) WO2006067141A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2649810A1 (fr) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Regime a base de cladribine pour traiter la sclerose en plaques
EP2343074A1 (fr) 2009-12-23 2011-07-13 Merck Serono S.A. Utilisation d'analogues de la purine pour traiter des maladies des voies respiratoires
WO2011117267A1 (fr) 2010-03-24 2011-09-29 Merck Serono Sa Traitement à la cladribine de la sclérose en plaques chez des groupes de patients définis par génotype
EP2428201A1 (fr) 2010-09-08 2012-03-14 Merck Serono S.A. Administration orale de nucléosides monophosphates
WO2012097867A1 (fr) 2011-01-18 2012-07-26 Synthon Bv Particules de cladribine et compositions pharmaceutiques comprenant celles-ci
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
JP2021504363A (ja) 2017-11-24 2021-02-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 進行型多発性硬化症の処置における使用のためのクラドリビン処方計画
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (fr) 1984-08-06 1990-05-29 Brigham Young University Preparation de composes a base de 2'-desoxyadenosine
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
PL321431A1 (en) 1994-12-22 1997-12-08 Ortho Pharma Corp Soluble 2-chloro-2'deoxyadenosine compositions
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (fr) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. Procede de production de 2-chloro-2'-desoxyadenosine (cladribine) et son derive 3,5-di-o-p-toluoyle
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
US7572909B2 (en) 2002-09-25 2009-08-11 Brigham Young University Method for the preparation of 2-halo-2′-deoxyadenosine compounds from 2′-deoxyguanosine
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
CN1761471A (zh) * 2003-02-25 2006-04-19 应用研究系统Ars股份公司 利巴韦林与干扰素β在脱髓鞘疾病中的联用
EA009714B1 (ru) 2003-03-28 2008-02-28 Арес Трейдинг С.А. Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
RS20050735A (en) 2003-03-28 2008-06-05 Ares Trading S.A., Cladribine formulations for improved oral and transmucosal delivery
CA2649810A1 (fr) * 2006-05-24 2007-11-29 Laboratoires Serono S.A. Regime a base de cladribine pour traiter la sclerose en plaques

Also Published As

Publication number Publication date
CY2018006I2 (el) 2018-06-27
AU2011200768B2 (en) 2012-09-13
BRPI0517132B8 (pt) 2021-05-25
PL2805723T3 (pl) 2018-04-30
AU2011200768A1 (en) 2011-03-17
US20090081163A1 (en) 2009-03-26
JP6092945B2 (ja) 2017-03-08
CY1112614T1 (el) 2016-02-10
EP2275110A2 (fr) 2011-01-19
ES2921858T3 (es) 2022-09-01
WO2006067141A1 (fr) 2006-06-29
IL183930A0 (en) 2007-10-31
LUC00064I2 (fr) 2018-03-28
LTPA2018503I1 (lt) 2018-03-12
EP2275110A3 (fr) 2011-04-27
JP2015180685A (ja) 2015-10-15
HRP20120228T1 (hr) 2012-04-30
DK2805723T3 (da) 2018-01-29
US7713947B2 (en) 2010-05-11
BRPI0517132B1 (pt) 2020-02-18
JP5795456B2 (ja) 2015-10-14
EP2263678B1 (fr) 2014-06-11
JP5908863B2 (ja) 2016-04-26
EA015799B1 (ru) 2011-12-30
US8377903B2 (en) 2013-02-19
JP6290962B2 (ja) 2018-03-07
NO20073813L (no) 2007-09-21
JP6430554B2 (ja) 2018-11-28
US20100203017A1 (en) 2010-08-12
JP2008524313A (ja) 2008-07-10
SI3332789T1 (sl) 2022-08-31
EP1827461B1 (fr) 2012-02-29
EP2805723B1 (fr) 2018-01-17
CY1119790T1 (el) 2018-06-27
IL212421A (en) 2014-01-30
EA200701221A1 (ru) 2008-02-28
EP2805723A1 (fr) 2014-11-26
JP2016138128A (ja) 2016-08-04
AU2005318190A1 (en) 2006-06-29
EP2263678A3 (fr) 2011-04-27
AU2005318190B2 (en) 2010-11-25
LUC00064I1 (fr) 2018-02-14
JP2013216664A (ja) 2013-10-24
CA2588966C (fr) 2020-07-21
EP4070800A1 (fr) 2022-10-12
CA3087419C (fr) 2023-03-07
CY2018006I1 (el) 2018-06-27
SI2805723T1 (en) 2018-02-28
CA3087419A1 (fr) 2006-06-29
CA2588966A1 (fr) 2006-06-29
MX2007007610A (es) 2007-08-03
KR20070091662A (ko) 2007-09-11
IL212421A0 (en) 2011-06-30
EP3332789B1 (fr) 2022-04-06
JP2018165271A (ja) 2018-10-25
LT3332789T (lt) 2022-07-25
JP2017101061A (ja) 2017-06-08
DK3332789T3 (da) 2022-07-11
EP2275110B1 (fr) 2013-07-10
EP2263678A2 (fr) 2010-12-22
PL3332789T3 (pl) 2022-08-22
EP1827461A1 (fr) 2007-09-05
LTC2805723I2 (lt) 2022-04-25
FR18C1008I1 (fr) 2018-03-30
HUE059133T2 (hu) 2022-10-28
SG160391A1 (en) 2010-04-29
AR052830A1 (es) 2007-04-04
EP3332789A1 (fr) 2018-06-13
JP2020193206A (ja) 2020-12-03
PL1827461T3 (pl) 2012-07-31
BRPI0517132A (pt) 2008-09-30
HUS1800009I1 (hu) 2018-05-02

Similar Documents

Publication Publication Date Title
FR18C1008I2 (fr) Regime posologique de cladribine pour le traitement de la sclerose en plaques
FR23C1003I2 (fr) Compositions et leurs utilisations pour le traitement de la Sclérose en plaques
EP1789086A4 (fr) Traitement prolonge de la sclerose en plaques
FR2907011B1 (fr) Utilisation de la citrulline pour le traitement des etats de denutrition
MA27395A1 (fr) Utilisation de prebiotiques pour le traitement et la prevention des syndromes hyper-glycemiques
EP1827491A4 (fr) Traitement de la sclerose en plaques
EP1750513A4 (fr) Utilisation de ligands gpcr54 pour le traitement de l'infertilite
MA29097B1 (fr) Composes pour le traitement des infections virales par flaviviridae
IL178846A0 (en) Solid dosage form of wetted heparin
FR2900341B1 (fr) Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer
IL179337A0 (en) Pharmaceutical compositions for the treatment of pruritus
AP2910A (en) Novel use of antihistamine agents for the preventative or early treatment of inflammatory syndromes,in particular those triggered by togaviruses
FR2886153B1 (fr) Composition destinee au traitement de la sclerose en plaques
FR2899128B1 (fr) Utilisation de filtres de deleucocytation pour la purification de defensines
FR2905868B1 (fr) Composition destinee au traitement de la sclerose laterale amyotrophique
FR2910813B1 (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
FR2901703B1 (fr) Utilisation de zatosetron pour le traitement de la rosacee, et compositions pharmaceutiques
FR2868312B1 (fr) Patch pour le traitement des levres
FR2962041B1 (fr) Inhibiteurs de la calpaine 3 pour le traitement de dystrophies musculaires et de cardiomyopathies
FR2875404B1 (fr) Composition pharmaceutique pour le traitement de la rosacee
FR2937550B1 (fr) Utilisation de la citrulline pour le traitement et la prevention du syndrome d'ischemie-reperfusion
FR2902321B1 (fr) Utilisation de curcumin pour le traitement de la canitie
FR2915099B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
FR2878160B1 (fr) Utilisation du n-acetyl-taurinate de magnesium pour la preparation de medicaments inhibiteurs de l'hypersensiblite photique
FR2908652B1 (fr) Utilisation d'ethoxuquine pour le traitement de la canitie